



























	 A	new	series	of	2,6‐diamino‐5‐arylazo‐4‐chloropyrimidine	analogues	(6‐13)	were	synthesizedfrom	 the	 pyrimidine	 scaffold	 5,	 via	 diazotization	 with	 various	 amines.	 Nucleophilic
displacement	 of	 compound	 5	 by	 ethanethiolate	 or	 arylthio	 nucleophiles,	 afforded	 the	 4‐
alkylthio	analogues	(14‐16).	Treatment	of	compound	17	or	18	with	thiourea	under	MWI	gave
the	 4‐thione	 derivatives	 19	 and	 20,	 respectively.	 On	 treatment	 of	 compound	 20	 with	 2‐
mercaptoacetic	acid	furnished	the	4‐thio	analogue	(21).	Reaction	of	compound	19	or	20	with
sodium	hypochlorite	 followed	by	ammonium	hydroxide	afforded	 the	4‐aminothio	analogues
22	 and	 23,	 respectively.	 Oxidation	 of	 compound	 23	 with	 H2O2	 led	 to	 the	 4‐sulphonamide
derivative	24.	All	new	compounds	were	evaluated	 for	 their	 in	vitro	 antiviral	activity	against












Pyrimidine	 and	 its	 derivatives	 demonstrated	 a	 diverse	
array	 of	 biological	 and	 pharmacological	 activities	 including	
antitumor	 [1‐6],	 antimicrobial	 [7‐10],	 and	 antihypertensive	
[11]	 in	 addition	 to	 their	 cardiovascular	 [12,13]	 and	 diuretic	
[14,15]	 properties.	 Some	 pyrimidine	 analogues	 exhibited	
potent	 antiviral	 activity	 against	 a	wide	 spectrum	of	 unrelated	
viruses,	such	as	poliovirus	[16]	and	herpes	virus	[17]	and	anti‐
HIV	 agents	 [18‐20],	 whereas	 two	 recent	 diarylpyrimidines	
(DAPY),	 rilpivirine	1	 [21]	and	etravirine	2	 [22,	23]	have	been	
classified	 as	 non‐nucleoside	 reverse	 transcriptase	 inhibitors	
(NNRTI's),	 meanwhile	 Chen	 et	 al.	 [24]	 have	 reported	 a	 new	
class	 of	 diarylpyrimidines	 (CHX‐DAPYs)	 as	 potent	 NNRTI's.	
Further,	 several	 pyrimidine	 derivatives	 exhibited	 significant	
antitumor	 activity	 e.g.	 imatinib	mesylate	 (Gleevec,	3)	 [25],	 an	
interesting	novel	agent	 for	 the	 treatment	of	chronic	Leukemia	
is	 the	 tyrosine	 kinase	 inhibitor	 which	 contains	 a	 4‐pyridyl‐
substituted	 pyrimidine‐2‐amine,	 in	 addition	 to	 a	 2,4‐diamino‐
N4‐6‐diaryl‐pyrimidines	 where	 the	 latter	 were	 identified	 to	
block	 the	 proliferation	 of	 tumor	 cell	 lines	 in	 vivo,	 especially	
duodenum	 cancer	 [26].	Monastrol	4	 [27]	 is	 another	model	 of	




Recently,	 Kim	 et	 al.	 [29]	 have	 reported	 some	 novel	
pyrimidine	derivatives	as	potent	acid	pump	antagonists	(APAs).	














In	 continuation	 of	 our	 ongoing	 work	 on	 the	 synthesis	 of	









Melting	 points	 are	 uncorrected	 and	 were	 measured	 on	 a	
Büchi	melting	point	apparatus	B‐545	 (Büchi	Labortechnik	AG,	
Switzerland).	 NMR	 data	 were	 obtained	 on	 400	 and	 600	MHz	




obtained	with	 a	 Vario,	 Elemental	 analyzer	 (Shimadzu,	 Japan).	
Analytical	 silica	 gel	 TLC	 plates	 60F254	 were	 purchased	 from	
Merck.	 Microwave	 supported	 reaction	 was	 performed	 in	 a	
SmithSynthesizer	(temperature	control	of	irradiation	power	up	










mL)	and	an	appropriate	 amine	 (1.00	mmol)	was	heated	 in	 an	
oil	bath	at	90‐100	°C	for	4‐5	h.	Then	water	(25	mL)	was	added,	




(6):	 From	 benzylamine	 (107	mg).	 Yield:	 110	mg	 (55%).	M.p.:	















8.0	Hz,	Harom.‐2'	 +	Harom.‐6'),	 6.60	 (br	 s.,	 2H,	NH2),	 4.73	 (d,	 2H,	
JNH,CH2	=	6.1	Hz,	HNCH2),	3.28	(d,	1H,	HNCH2).	13C	NMR	(150.91,	
DMSO‐d6,	δ,	ppm):	163.2	(C(2)pyrimid.),	161.5	(C(4)pyrimid.),	157.6	
(C(2')picolyl),	 152.0	 (C(6)pyrimid.),	 149.5	 (C(6')picolyl),	 141.6	
(C(4')picolyl),	 131.7,	 122.9,	 122.1	 (Carom.),	 119.3	 (C(3')picolyl	 +	




pyrimidine	 (8):	 From	 dimethylamine	 (45	 mg).	 Yield:	 124	 mg	
(74%).	M.p.:	 204‐207	 °C	 (Dec.).	Rf	 =	 0.55.	 1H	NMR	 (400	MHz,	
DMSO‐d6,	δ,	ppm):	7.79	(br	s.,	2H,	NH2),	7.61	(d,	2H,	J	=	7.9	Hz,	
H‐Ar),	7.54	(d,	2H,	J	=	7.9	Hz,	H‐Ar),	6.81	(br	s.,	2H,	NH2),	3.31	
(s,	6H,	NMe2).	 13C	NMR	(DMSO‐d6,	δ,	 ppm):	163.0	 (C(2)pyrimid.),	
161.5	 (C(4)pyrimid.),	 156.0	 (C(6)pyrimid.),	 132.5,	 130.2,	 126.5	
(Carom.),	 122.9	 (C‐Br),	 104.1	 (C(5)pyrimid.),	 39.1	 (NMe2).	 Anal.	
calcd.	 for	 C12H14BrN7:	 C,	 42.87;	 H,	 4.20;	 N,	 29.16.	 Found:	 C,	
42.66;	H,	4.08;	N,	28.98	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐diethylamino	
pyrimidine	 (9):	 From	 diethylamine	 (73	 mg).	 Yield:	 126	 mg	




(150.91,	 DMSO‐d6,	 δ,	 ppm):	 163.0	 (C(2)pyrimid.),	 162.0	
(C(4)pyrimid.),	 157.2	 (C(6)pyrimid.),	 132.1,	 130.6,	 127.9	 (Carom.),	
121.6	 (C‐Br),	 100.0	 (C(5)pyrimid.),	 41.6	 (2xCH2CH3),	 11.4	
(2xCH2CH3).	 Anal.	 calcd.	 for	 C14H18BrN7:	 C,	 46.16;	 H,	 4.98;	 N,	
29.92.	Found:	C,	45.89;	H,	4.88;	N,	28.68	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐diphenylamino	
pyrimidine	 (10):	 From	diphenylamine	 (169	mg).	 Yield:	 83	mg	












4H,	 2xCH2(piperidin)),	 1.65‐1.50	 (m,	 6H,	 3xCH2(piperidin)).	 13C	 NMR	
(150.91,	 DMSO‐d6,	 δ,	 ppm):	 162.7	 (C(2)pyramid.),	 160.8	
















2H,	 NH2),	 3.88	 (m,	 4H	 2xCH2(morpholin),	 3.71	 (m,	 4H,	
2xCH2(morpholin).	 13C	 NMR	 (150.91,	 DMSO‐d6,	 δ,	 ppm):	 163.3	
(C(2)pyrimid.),	161.3	(C(4)pyrimid.),	156.8	(C(6)pyrimid.),	132.6,	130.6,	








2H,	 NH2),	 3.30	 (br	 s.,	 1H,	 NH),	 3.09	 (br	 s.,	 4H,	 2xCH2(piperazin),	
2.89	 (br	 s.,	 4H,	 2xCH2(piperazin).	 13C	 NMR	 (150.91,	 DMSO‐d6,	 δ,	
ppm):	163.7	(C(2)pyrimid.),	162.2	(C(4)pyrimid.),	157.1	(C(6)pyrimid.),	









mL)	 and	 sodium	 ethanethiolate,	 sodium	 thiophenolate	 or	 p‐
chlorobenzenethiol	 (0.90	mmol)	was	 heated	 in	 an	 oil	 bath	 at	
90‐100	°C	for	4‐6	h.	After	cooling,	the	solution	was	evaporated	
and	the	residue	was	co‐evaporated	with	toluene	(4×15	mL)	to	
give	 a	 crude	 solid.	 Recrystallization	 from	 ethanol	 or	
ethanol:ether	 (1:3,	 v:v)	 afforded	 the	 desired	 product	 (Scheme	
2).	
5‐((4‐Bromophenyl)diazenyl)‐6‐(ethylthio)pyrimidine‐2,4‐
diamine	 (14):	 From	 sodium	 ethanethiolate	 (76	mg).	 Yield:	 81	
mg	 (74%).	 M.p.:	 236‐238	 °C.	 Rf	 =	 0.63.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	δ,	ppm):	9.26	 (br	 s.,	2H,	NH2	 ),	8.19	(br	s.,	2H,	NH2),	
7.72	(d,	2H,	J	=	7.9	Hz,	Harom.‐3'	+	Harom.‐5'),	7.69	(d,	2H,	J	=	7.9	
Hz,	Harom.‐2'	+	Harom.‐6'),	3.99	(q,	2H,	J	=	7.1	Hz,	CH2CH3),	1.23	(t,	









MHz,	DMSO‐d6,	 δ,	 ppm):	 8.32	 (br	 s.,	 2H,	NH2),	 8.19	 (br	 s.,	 2H,	
NH2),	 7.90‐7.59	 (m,	 9H,	Harom.).	 13C	NMR	 (150.91,	DMSO‐d6,	 δ,	
ppm):	181.4	(C(4)pyrimid.),	164.6	(C(2)pyrmid.),	156.0	(C(6)pyrimid.),	
133.5,	 132.2,	 132.1,	 129.0,	 127.8,	 123.8	 (Carom.),	 122.1	 (C‐Br),	
118.1	 (C(5)pyrimid.).	 MS	 ((+)‐FAB):	m/z	 =	 401/402	 [M]+.	 Anal.	





benzyl)thio)pyrimidine	 (16):	 From	 4‐chlorobenzylthiol	 (143	
mg).	Yield:	74	mg	(53%).	M.p.:	232‐236	°C	(Dec.).	Rf	=	0.55.	1H	
NMR	 (400	MHz,	DMSO‐d6,	 δ,	 ppm):	9.26	 (br	 s.,	2H,	NH2),	 8.19	
(br	s.,	2H,	NH2),	7.75‐7.29	(m,	8H,	Harom.),	4.36	(s,	2H,	CH2).	13C	
NMR	 (150.91,	 DMSO‐d6,	 δ,	 ppm):	 164.6	 (C(4)pyrimid.),	 161.1	
(C(2)pyrmid.),	155.9	(C(6)pyrimid.),	132.2,	132.0,	131.1,	128.4,	123.2	
(Carom.),	 122.1	 (C‐Br),	 118.6	 (C(5)pyrimid.),	 31.2	 (CH2).	 MS	 ((+)‐








irradiated	 in	 a	 microwave	 oven	 (800	 W)	 for	 25	 min.	 The	
mixture	was	poured	 into	 ice‐cold	water	 and	 the	 solid	 residue	
was	 washed	 with	 ether	 followed	 by	 a	 little	 amount	 of	 cold	
ethanol.	 Recrystallization	 from	 ethanol	 afforded	 the	 desired	
product	(Scheme	3).	
2‐Amino‐6‐(benzyloxy)pyrimidine‐4‐thione	 (19):	 Yield:	 76	
mg	 (71%).	 M.p.:	 136‐138	 °C.	 Rf	 =	 0.57.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	 δ,	 ppm):	 7.42‐7.33	 (m,	 5H,	 Harom.),	 7.07	 (br	 s.,	 2H,	
NH2),	6.15	(s,	1H,	NH),	5.31	(s,	1H,	Hpyrimid.‐5),	5.13	(s,	2H,	CH2).	
13C	 NMR	 (150.91,	 DMSO‐d6,	 δ,	 ppm):	 184.3	 (C6=S),	 170.3	
(C(4)pyrimid.),	154.7	 (C(2)pyrimid.),	137.1	 (C(1')arom.),	128.9,	128.8,	
128.4,	 128.2	 (Carom.),	 94.7	 (C(5)pyrimid.),	 65.7	 (CH2).	 Anal.	 calcd.	
for	C11H11N3OS:	C,	56.63;	H,	4.75;	N,	18.01.	Found:	C,	56.41;	H,	
4.65;	N,	17.82	%.	
2‐Amino‐6‐methoxypyrimidine‐4‐thione	 (20):	 Yield:	 76	 mg	
(67%).	M.p.:	 289‐292	 °C	 (Dec.).	Rf	 =	 0.37.	 1H	NMR	 (400	MHz,	
DMSO‐d6,	δ,	ppm):	7.28	(br	s.,	2H,	NH2),	6.76	(s,	1H,	NH),	5.35	
(s,	1H,	Hpyrimid.‐5),	4.07	(s,	3H,	OCH3).	 13C	NMR	(150.91,	DMSO‐
d6,	 δ,	 ppm):	 184.9	 (C=S),	 171.8	 (C(4)pyrimid.),	 153.8	 (C2)pyrimid.),	








mercaptoacetic	 acid	 (30	mg,	 0.32	mmol)	 and	 stirred	 at	 room	
temperature	 for	 16	 h.	 After	 cooling,	 the	mixture	 was	 filtered	
and	 the	 filtrated	 was	 evaporated	 to	 dryness	 and	 the	 residue	
was	 purified	 on	 a	 short	 column	 of	 SiO2	 (5	 g).	 Elution	 with	
chloroform:methanol	(95:5,	v:v)	afforded	compound	21	(35	mg,	
47%)	 (Scheme	 3).	 M.p.:	 142‐154	 °C	 (Dec.).	 Rf	 =	 0.1.	 1H	 NMR	
(400	MHz,	DMSO‐d6,	δ,	ppm):	10.95	(s,	1H,	OH),	7.23	(br	s.,	2H,	
NH2),	 6.33	 (s,	 1H,	 Hpyrimid.‐5),	 4.08	 (s,	 2H,	 CH2),	 3.88	 (s,	 3H,	
OMe).	 13C	NMR	(150.91,	DMSO‐d6,	δ,	ppm):	71.7	(CO2H),	170.6	

















Compound	 21	 (104	 mg,	 0.66	 mmol)	 or	 20	 (54	 mg,	 0.34	
mmol)	was	added	to	a	solution	of	sodium	hypochlorite	(5	mL)	
and	 the	 reaction	 mixture	 was	 stirred	 at	 60	 °C	 for	 4	 h.	
Ammonium	 hydroxide	 (10	 mL)	 was	 added	 to	 the	 reaction	
mixture,	and	stirred	for	an	additional	1	h	at	room	temperature,	
the	 precipitate	 was	 filtered	 and	 washed	 with	 water	 several	




DMSO‐d6,	 δ,	 ppm):	 7.43‐7.33	 (m,	 5H,	 Harom.),	 7.33	 (br	 s.,	 2H,	
NH2),	6.14	(s,	1H,	Hpyrimid.‐5),	5.39	(br	s.,	2H,	SNH2),	5.31	(s,	2H,	
CH2).	13C	NMR	(150.91,	DMSO‐d6,	δ,	ppm):	189.4	(CSNH2),	166.1	
(C(4)pyrimid.),	 160.5	 (C2)pyrimid.),	 129.0‐126.9	 (Carom.),	 100	
(C(5)pyrimid.).	 Anal.	 calcd.	 for	 C11H12N4OS:	 C,	 53.21;	 H,	 4.87;	 N,	
22.56.	Found:	C,	52.98;	H,	4.70;	N,	22.68	%.	
2‐Amino‐4‐(aminothio)‐6‐methoxypyrimidine	(23):	Yield:	36	
mg	 (61%).	 M.p.:	 288‐291	 °C.	 Rf	 =	 0.43.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	δ,	ppm):	7.41	(br	s.,	2H,	NH2),	5.99	(s,	1H,	Hpyrimid.‐5),	
3.87	(s,	3H,	OMe),	2.31	(s,	2H,	SNH2).	13C	NMR	(150.91,	DMSO‐
d6,	 δ,	 ppm):	 189.0	 (C(6)pyrimid.),	 167.8	 (C4)pyrimid.),	 153.2	









was	 evaporated	 to	 dryness	 and	 the	 residue	was	washed	with	





3.98	 (s,	 3H,	OMe),	 2.11	 (br	 s.,	 2H,	 SO2NH2).	 13C	NMR	 (150.91,	
DMSO‐d6,	 δ,	 ppm):	 168.9	 (C(6)pyrimid.),	 165.1	 (C4)pyrimid.),	 154.7	








Recently,	 reported	 the	 synthesis	 of	 azopyrimidine	5	 [33],	
and	selected	here	as	a	starting	material	for	the	synthesis	of	new	
azopyrimidine	analogues	having	alkyl	and	aryl	amino	groups	at	
C‐4.	 Thus,	 compound	 5	 was	 subjected	 to	 a	 nucleophilic	
displacement	 of	 chlorine	 group	 by	 treatment	 with	 various	
amines	 in	 DMF	 at	 90‐100	 °C	 for	 4‐5	 h,	 leading	 to	 the	 new	
derivatives	6‐13	in	good	to	moderate	yields	(55‐89	%),	except	
the	products	7	and	10	were	obtained	in	a	lower	yields	32	and	












and	 C‐4	 of	 the	 pyrimidine	 scaffold	 resonated	 at	 the	 region	 δ	
164.0‐163.2	 ppm	 and	 the	 region	 δ	 162.3‐160.0	 ppm,	
respectively.	C‐5	and	C‐6	appeared	at	the	regions	δ	110.1‐100.0	
and	157.7‐152.0	ppm,	respectively.	The	aromatic	carbon	atoms	
C‐4'	 carrying	 bromine	 residue	 were	 resonated	 the	 regions	 δ	
123.8‐118.9	ppm,	while	 the	aromatic	carbon	atoms	C‐1'	 ‐	C‐6'	
of	 the	 pyrimidine	 analogues	 6‐13	 were	 resonated	 at	 the	
regions	 δ	140.8‐122.6	 ppm.	 The	 aliphatic	 carbon	 atoms	were	
fully	analyzed	(cf	Experimental	section).		
Next,	 the	 analogue	 5	 was	 used	 as	 a	 precursor	 for	 the	
synthesis	 of	 new	 5‐arylazo‐4‐ethyl(aryl)thio‐pyrimidine	 deri‐
vatives	to	examine	their	antiviral	activity	in	comparison	to	the	
azoaryl	 analogues	6‐13.	 Thus,	 treatment	 of	 compound	5	with	





1H	 and	 13C	 NMR	 spectra.	 The	 1H	 NMR	 spectra	 showed	 rather	
similar	 patterns	 for	 the	 phenyl	 and	 ethyl	 protons.	 The	
methylene	 and	 methyl	 protons	 of	 SEt	 group	 appeared	 as	





































C‐6	 together	with	 the	 aromatic	 carbon	 atoms	were	 identified.	
However,	 compound	 14	 has	 been	 selected	 for	 further	 NMR	
experiment.	 In	 the	 gradient‐selected	 HMBC	 spectrum	 [34]	 of	
compound	 14,	 C‐4	 of	 the	 pyrimidine	 ring	 at	 δ	 163.0	 ppm	
showed	 a	 2JC,H	 coupling	 with	 methylene	 protons	 of	 CH3CH2S	
group	 at	 δ	 3.99	 ppm,	 in	 addition	 to	 a	 3JC,H	 coupling	 with	 the	
methyl	 protons	 of	 the	CH3CH2S	 group	 at	δ	 1.23	ppm.	 Further,	
the	aromatic	protons	H‐3'	and	H‐5'	at	δ	7.72	ppm	revealed	two	
2JC,H	 coupling	with	 C‐4'	 (C‐Br)	 of	 the	 aromatic	 ring	 at	 δ	 121.6	
ppm,	 while	 the	 same	 carbon	 atom	 (C‐Br)	 showed	 two	 3JC,H	





with	 thiourea	 under	 microwave	 irradiation	 (MWI)	 in	 a	 free	
solvent	 condition	 for	 15	 min	 afforded,	 after	 purification,	 the	
pyrimidine‐thione	analogues	19	and	20	 in	71	and	67	%	yield,	
respectively.	 Treatment	 of	 compound	 20	 with	 2‐mercapto	
acetic	 acid	 in	 DMF	 in	 the	 presence	 of	 K2CO3	 at	 room	
temperature	 for	 16	 h	 afforded	 regioselectively	 [36],	 after	
chromatographic	purification,	4‐thio‐ethylacetic	acid	derivative	
21	(47	%).	
Next,	 treatment	 of	 compound	 19	 and	 20	 with	 sodium	
hypochlorite	followed	by	ammonium	hydroxide,	following	Rice	
et	 al.	 method	 [37],	 furnished	 after	 purification,	 the	 4‐
aminothio‐pyrimidine	 derivatives	 22	 and	 23	 in	 61	 and	 68%	
yield,	 respectively.	 Oxidation	 of	 compound	 23	 with	 H2O2	 at	
room	 temperature	 afforded,	 after	 chromatographic	 purify‐
cation,	the	sulfonamide	24	in	74%	yield	(Scheme	3).	
The	 structures	 of	 compound	19‐24	 were	 elucidated	 from	
their	 1H	 and	 13C	 NMR	 spectra.	 In	 the	 1H	 NMR	 spectra	 of	
compounds	 19	 and	 20,	 H‐5	 of	 the	 pyrimidine	 ring	 were	
appeared	 at	 δ	 5.31	 and	 5.39	 ppm,	 respectively,	 whereas	 the	
protons	 of	 the	 amino	 groups	 at	 C‐2	were	 resonated	 as	 broad	
singlet	at	δ	7.07	and	7.33	ppm,	respectively.	The	SNH2	protons	
of	 compound	22	 resonated	 as	 a	 broad	 singlet	 at	 δ	5.39	 ppm,	
while	the	singlet	and	broad	singlet	at	δ	6.76	and	2.31	ppm	were	
assigned	 to	 NH	 proton	 of	 the	 pyrimidine	 thione	 20	 and	 the	
SNH2	 protons	 at	 C‐4	 of	 the	 analogue	 23,	 respectively.	 The	
singlets	 at	δ	5.35	and	5.99	ppm	were	attributed	 to	H‐5	of	 the	
pyrimidine	ring,	 in	addition	to	 two	singlets	at	δ	4.07	and	4.09	
ppm,	 assigned	 to	 the	methoxy	 group	 at	 C‐6	 of	 compound	20	
and	23,	 respectively.	Compound	24	 showed	singlet	and	broad	





ppm,	 respectively.	 C‐2,	 C‐4	 and	 C‐5	 together	 with	 the	











The	 results	 are	 summarized	 in	 Table	 1,	 in	which	 the	 data	 for	










6 IIIB >	45.23 45.23	 <	1
ROD >	45.23 45.23	 <	1
7	 IIIB	 >	65.23	 65.23	 <	1	
ROD	 >	65.23	 65.23	 <	1	
8	 IIIB	 >	32.60	 32.60	 <	1	
ROD >	32.60 32.60	 <	1
9 IIIB >	53.60 53.60	 <	1
ROD >	53.60 53.60	 <	1
10 IIIB >	35.10 35.10	 <	1
ROD >	35.10 35.10	 <	1
11 IIIB >	12.35 12.35	 <	1
ROD >	12.35 12.35	 <	1
12	 IIIB	 >	28.05	 28.05	 <	1	
ROD	 >	28.05	 28.05	 <	1	
13	 IIIB	 >	10.04	 10.04	 <	1	
ROD >	10.04 10.04	 <	1
14	 IIIB	 >	2.12	 2.12	 <	1	
ROD >	2.12 2.12	 <	1
15 IIIB >	1.99 1.99	 <	1
ROD >	1.99 1.99	 <	1
16 IIIB >	1.80 1.80	 <	1
ROD >	1.80 1.80	 <	1
19	 IIIB	 >	11.34	 11.34	 <	1	
ROD	 >	11.34	 11.34	 <	1	
20 IIIB >	5.67 5.67	 <	1
ROD	 >	5.67	 5.67	 <	1	
21	 IIIB	 >	1.92	 1.92	 <	1	
ROD >	1.92 1.92	 <	1
22 IIIB >	3.38 3.38	 <	1
ROD >	3.38 3.38	 <	1
23 IIIB >	5.98 5.98	 <	1
ROD >	5.98 5.98	 <	1
24 IIIB >	10.18 10.18	 <	1
ROD >	10.18 10.18	 <	1
AZT IIIB 0.0022 >	25	 >	11363
ROD >	25 >	25	 >	26596
Nevirapine	 IIIB	 0.050	 0.050	 >	80	






























or	 arylamino	 substituents	 at	 C‐4	 of	 the	 same	 ring;	 e.	 g.:	






The	molecular	 docking	was	 performed	 using	 SYBYL‐X	 1.1	
and	 the	 docking	 results	 were	 shown	 by	 PyMOL	 [42].	 Our	
molecular	docking	analysis	of	the	new	analogues	based	on	the	
modeling	 study,	 which	 was	 performed	 to	 understand	 the	
binding	 mode	 of	 these	 analogues	 with	 the	 HIV‐RT	 binding	
pocket	(NNIBP)	(PDB	code:	3DLG,	[43]).	
Compound	15	has	been	selected	 for	 the	docking	modeling	
study,	 since	 its	 binding	 energy	 score	 ‐8.01,	 indicating	 a	
selectivity	 and	potency	profiles	 of	 substituted	 aryl‐azopyrimi‐
dine	 to	 bind	 the	 active	 site	 of	 HIV‐RT	 pocket	 (Figure	 3).	 As	
shown	 in	 figure	 3,	 the	 aromatic	 rings	 of	 compound	15	 fitted	
into	 an	 aromatic	 rich	 subpocket	 surrounded	 by	 the	 aromatic	
side	 chains	 of	 Tyr179	 and	 Tyr186.	 The	 pyrimidine	 backbone	
was	located	in	the	middle	of	the	binding	pocket,	anchoring	the	














and	 2.	 Compounds	14‐16	 and	21	 exhibited	 potential	 activity	
against	HIV‐1,	whereas	 the	others	 analogues	 shown	moderate	
to	 poor	 activity.	 Compound	 15	 have	 been	 selected	 for	 the	
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